首页> Future oncology (London, England)> Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

Temozolomide in secondary prevention of HER2-positive breast cancer brain metastases.

导出 OA

翻译打印收藏纠错

第一作者： Alexandra S,Zimmer

第一单位： Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA.

作者： Alexandra S,Zimmer ^[1] ; Seth M,Steinberg ^[2] ; Dee Dee,Smart ^[3] ; Mark R,Gilbert ^[4] ; Terri S,Armstrong ^[4] ; Eric,Burton ^[4] ; Nicole,Houston ^[1] ; Nadia,Biassou ^[5] ; Brunilde,Gril ^[1] ; Priscilla K,Brastianos ^[6] ; Scott,Carter ^[7] ; David,Lyden ^[8] ; Stanley,Lipkowitz ^[1] ; Patricia S,Steeg ^[1]

作者单位： Women's Malignancies Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA. ^[1] Biostatistics & Data Management Section, National Cancer Institute, NIH, Bethesda, MD 20814, USA. ^[2] Radiation Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA. ^[3] Neuro-Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20814, USA. ^[4] Neuro-Radiology, Clinical Center, NIH, Bethesda, MD 20814, USA. ^[5] Central Nervous System Metastases Program, Massachusetts General Hospital/Harvard Cancer Center Boston, MA 02114, USA. ^[6] Biostatistics and Computation Biology, Dana-Farber Cancer Institute, Boston, MA 02114, USA. ^[7] Pediatric Hematology Oncology, Weill Cornell Medicine, New York, NY 10065, USA. ^[8]

关键词 T-DM1 brain metastases metastatic breast cancer secondary prevention temozolomide